Link Copied

These are the coronavirus vaccines under human trials right now

These are the coronavirus vaccines under human trials right now
BCCL
  • Globally, there are at least 19 vaccines under human trials.
  • Of the total, three of the institutions have managed to reach the final Phase III trials —the University of Oxford and China’s state-owned pharmaceutical Sinopharm and Sinovac.
  • China — the country where coronavirus first broke — has at least five vaccine candidates under human trials.

Seven months into the coronavirus pandemic, there’s still no cure for the disease. In fact, the Health Organisation believes the coronavirus crisis, in the coming future, is only going to be “worse and worse and worse.”


Globally, there are at least 19 vaccines under human trials. Of the total, three of the institutions have managed to reach the final Phase III trials —the University of Oxford and China’s state-owned pharmaceutical Sinopharm and Sinovac.

China — the country where coronavirus first broke — has at least five vaccine candidates under human trials.


These are the coronavirus vaccine under human trials right now


ChAdOx1-S — the University of Oxford coronavirus vaccine candidate

ChAdOx1-S — the University of Oxford coronavirus vaccine candidate

University of Oxford’s coronavirus vaccine candidate is the most advanced vaccine candidate against COVID-19 under Phase II trial — which involves thousands of participants in South Africa, UK, and Brazil. Oxford says the potential coronavirus vaccine could be ready by September.

Advertisement

​Sinopharm— China’s state-owned pharmaceutical company — is the first in the world to start Phase III trials

​Sinopharm— China’s state-owned pharmaceutical company — is the first in the world to start Phase III trials

Chinese pharmaceutical, Sinpharm, is the first in the world to start Phase III trials on a potential coronavirus vaccine. The vaccine is being developed in Wuhan — the same place where coronavirus first originated.

The company is working on an “inactivated” vaccine which is produced after scientists are able to grow the virus again in a lab setting and kill it.

Advertisement

​ZyCov-D, a potential coronavirus vaccine candidate by Zydus Cadila

​ZyCov-D, a potential coronavirus vaccine candidate by Zydus Cadila
BCCL

(Representative image)

Drug firm Zydus Cadila on Wednesday said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D.In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India.

The adaptive phase I/ II human clinical trials of ZyCoV-D have commenced with the first human dosing, it said, adding that the adaptive phase I/II dose-escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine. The entire trial is expected to be completed in a year.

Advertisement
Advertisement

​CoronaVac by Sinovac Biotech might be available by autumn

​CoronaVac by Sinovac Biotech might be available by autumn

Chinese pharmaceutical Sinovac Biotech on July 16 got the approval to conduct Phase III clinical trial for its coronavirus vaccine candidate, CoronaVac. The company will now hire 9,000 health professionals who are currently working in a COVID-19 facility in Brazil and will start the clinical trial this month.

It started developing COVID-19 vaccine as early as January 28. It aims to introduce its coronavirus vaccine this year.

Advertisement

​COVAXIN, India’s first indigenous COVID-19 vaccine candidate by Bharat Biotech and ICMR

​COVAXIN, India’s first indigenous COVID-19 vaccine candidate by Bharat Biotech and ICMR
BCCL

COVAXIN — developed by the Indian vaccine and biotherapeutics manufacturer Bharat Biotech — is the first COVID-19 vaccine candidate in the country to get DGCI’s (Drug Controller General of India) nod. DGCI has allowed the company to conduct phase I and Phade II clinical trials. ICMR aims to launch the vaccine by August 15.

There are several firms whose coronavirus vaccine are likely to go under human trials soon like Moderna

Advertisement

​mRNA-1273, Moderna’s vaccine candidate to begin human trials on July 23

​mRNA-1273, Moderna’s vaccine candidate to begin human trials on July 23

The US-based biotech firm Moderna said on July 14 that it would enter the final stage of human trials for its COVID-19 vaccine on July 27 after the vaccine showed promising results. The Phase 3 trials are likely to have 30,000 volunteers in the US. Half of the participants will be given a 100 mg dose of the vaccine while the other half will receive a placebo. Moderna’s vaccine, if proven successful, could be available by the end of the year or early 2021.

Some of the other institutions whose vaccine candidate which are in the Phase I of the clinical trial include Medicago Inc., Walvax Biotech, Curevac, Imperial College London, University of Queensland, Vaxine Pty Ltd, Clover Biopharmaceuticals, Gamaleya Research Institute, Genexine Consortium and Pfizer.




SEE ALSO:

Jio Glass – Akash Ambani and Isha Ambani announce Reliance’s latest product which offers holographic video calls

Wipro share price 16% increase leads to surge in Infosys share price too

Moderna's COVID-19 vaccine will be in final stages of human trial starting July 27

Advertisement
COVID-19IndiaCases: 2.26MDeaths: 45.2kRecovered: 1.58M
COVID-19WorldCases: 19.71MDeaths: 728kRecovered: 12.22M
COVID-19USACases: 4.95MDeaths: 160kRecovered: 1.67M